Shuttle Unloads More Gantenerumab Into the Brain
New data presented at the AD/PD conference offer the first evidence that a brain-shuttle strategy can work in people; the lecanemab and aducanumab antibody programs offer small updates.
ALL NEWS
6587 RESULTS
Sort By:
- Most Recent
- Most Commented
Blood Tests Go Head-to-Head in Community Cohorts
A cast of blood biomarkers for Alzheimer's has emerged from studies in research cohorts, and is now being put to the test in community cohorts. At AAIC, direct comparisons of top contenders showed that some detect amyloid and impending cognitive decline.
Could Personalizing Multimodal Interventions Give Them Oomph?
In a small pilot study, tailoring lifestyle changes to the individual boosted cognition, with an effect size three times that seen in the Finger trial.
Living in Greener Pastures May Cut Risk for Alzheimer’s, Parkinson’s
The more foliage near a person’s residence, the less likely they are to have either disease.
Cold-Shock Protein Reinvigorates Synapses
A protein that repairs synapses after hibernation falters in some models of neurodegenerative diseases.
Clinical Trials on Alzheimer's Disease (CTAD) 2022
Dare We Say Consensus Achieved: Lecanemab Slows the Disease Brexpiprazole Eases Agitation in People with AD; So Does Being in a Trial Two New Stabs at Vaccinating People Against Pathologic Tau Cognitive Tests Taken at Home Are on Par with In-Clinic Assess
After Hibernation, Bears Clear P-Tau Aggregates
Plasma p-tau climbs as bears sleep. Post-torpor, tau reverts to normal. Does neuronal metabolic activity have to do with it?
U.S. House Scolds FDA Over Aduhelm Approval
In a 45-page report, two House committees rebuked the agency for working too closely with drug sponsor Biogen.
U.S. FDA Gives Green Light to Leqembi, aka Lecanemab
Eisai’s anti-amyloid antibody got the nod via the accelerated approval pathway; the company is expected to apply for traditional approval within days.
Goodbye Antibodies, Hello AlzAntibodies: New Database Is Growing on Alzforum
A collection of antibodies against microglial proteins is starting off a new database on Alzforum.
Should People on Blood Thinners Forego Leqembi?
Recent reports of three deaths in the lecanemab extension study suggest that blood thinners, lecanemab, and cerebral amyloid angiopathy could be a dangerous combination.
Neuroinflammation Field Grapples With Complexity at Keystone Symposia
Researchers explored how the brain’s immune cells influence disease, and how cells and signals from outside the brain pitch in.
Just Like Viruses, Tau Can Unleash Interferons
By triggering release of mitochondrial DNA, tau fibrils may set off a cytosolic sensor that activates the interferon response. Blocking this sensor spared neurons and memory in mice.
In Progressive Supranuclear Palsy, Filamin-A Goads Tau Aggregation
The actin-binding protein associated with tau aggregates in people with PSP, and rare variants in the gene associated with the disease.
2022, a Year in Review
Therapeutics research in the field ended on high hopes that lecanemab’s Phase 3 data would carry this anti-Aβ antibody to regulatory approval in country after country in 2023. This wave drew power from progress in biomarker research; but alas, much work remains to be done.
Current Filters
No filters selected